1. Introduction {#sec0005}
===============

Dengue has become the main arthropod-borne viral disease in several tropical and subtropical countries, causing more than 50--100 million cases and 500,000 hospitalizations annually around the world ([@bib0105]). Disease manifestations cover a wide spectrum ranging from dengue with or without warning signs to severe dengue, in which plasma leakage, hemorrhage and organ impairment can lead to death ([@bib0290]). The disease is caused by one of four *Dengue virus* (DENV) serotypes (DENV-1 to -4), which are enveloped, single-stranded and positive-sense RNA viruses belonging to the *Flavivirus* genus within the *Flaviviridae* family ([@bib0180]). These viruses possess a short genome of approximately 10.7 kb with a type 1 cap structure (m^7^GpppAmpN~2~) at the 5′end, two highly structured untranslated regions (UTRs) at the 5′ and 3′ ends, a long open reading frame (ORF) encoding a single viral polyprotein and lacking a polyadenylate tail at the 3′ end. After proteolytic processing, three structural and seven non-structural proteins are generated from the viral polyprotein ([@bib0015]).

Several *cis*-acting elements at the 5′UTR \[stem-loops SLA and SLB, upstream the AUG region (5′UAR)\], at the capsid-coding region \[downstream AUG region (5′DAR), capsid-hairpin (cHP), 5′ cyclization sequence (5′CS), downstream 5′CS (dCS), CCR1\] and at the 3′UTR \[highly variable region (HVR), semi-variable region (SVR), pseudoknots (PK2 and PK1), 3′CS, 3′DAR, 3′UAR and 3′ stem-loop (3′SL)\] are critical for virus replication, translation or assembly ([@bib0075], [@bib0080], [@bib0095], [@bib0235]).

The role of the DENV proteins and the UTRs of the RNA genome in viral genome replication ([@bib0180]), post-translational cleavage ([@bib0065]), virion morphogenesis \[reviewed in ([@bib0215])\], regulation of the host immune response ([@bib0210], [@bib0205]) and virus entry into susceptible cells through receptor-mediated endocytosis ([@bib0050], [@bib0115]) and membrane fusion for the release of virions into the cytoplasm ([@bib0200]) have been partially clarified.

Although there is not an effective and available antiviral therapy or vaccine and many aspects of the DENV biology remain unclear, the major progress during the last two decades in the study of this virus, particularly in identifying *cis*-acting elements regulating translation and replication, has resulted from the use of infectious clones and replicons obtained through reverse genetics ([@bib0235]). This technology has also been important in identifying and evaluating adaptive mutations and virulence determinants, due to the possibility of generating mutations in specific viral genes or RNA elements, whose effect on viral RNA replication and pathogenesis can be assessed *in vitro* and *in vivo*, respectively ([@bib0045], [@bib0070], [@bib0075], [@bib0090], [@bib0130], [@bib0170], [@bib0190], [@bib0295]). Infectious clones and derived replicons lacking structural components necessary for virus assembly and propagation have also shown potential for the development and characterization of live-attenuated viruses as vaccine candidates ([@bib0125], [@bib0140], [@bib0300]), genetic vaccines ([@bib0225]) and high-throughput platforms for screening of chemical antiviral compounds ([@bib0040], [@bib0120], [@bib0165], [@bib0260], [@bib0305]) and siRNAs ([@bib0220]). In addition, infectious clones with reporter genes fused to some of the structural proteins become a powerful tool in cell biology of viral infection for subcellular localization of viral proteins and for tracking the viral particles during the entry, maturation and exit steps of the vital cycle ([@bib0025]).

Common strategies for the construction of infectious cDNAs from DENV genomes through reverse genetics have been based on standard high-copy and low-copy number plasmids ([@bib0100], [@bib0150], [@bib0155], [@bib0275]). However, the high instability of the full-length clones leading to rearrangements and unsuccessful clone rescue has been a common problem when using some of these backbones ([@bib0285]). To overcome this problem, yeast artificial chromosomes and yeast-*Escherichia coli* shuttle vectors have been successfully used with higher stability ([@bib0140], [@bib0135], [@bib0245], [@bib0250], [@bib0255]). More recently, DENV-1 and -2 infectious cDNAs have been cloned into bacterial artificial chromosomes (BACs) ([@bib0055], [@bib0240], [@bib0285]), a system facilitating the stable cloning of inserts up to 300 kb, as there are typically only one or two copies of the BAC per cell ([@bib0145], [@bib0270]). However, these DENV infectious clones have been constructed under the control of the prokaryotic T7 promoter, requiring *in vitro* transcription (Run-off) and subsequent transfection of the synthesized RNAs. One decade ago, the first stable cloning of the transmissible gastroenteritis virus (TGEV) under the transcriptional control of the eukaryotic cytomegalovirus (CMV) immediate-early promoter was demonstrated ([@bib0005]). TGEV, as a member of the coronavirus genus, has one of the largest RNA genomes of approximately 30 kb in length, thus demonstrating the functional stable cloning of that genome into infectious cDNAs ([@bib0160]) and the opportunity for DNA-launched transcription from an eukaryotic promoter, avoiding expensive *in vitro* transcription and the subsequent manipulation of transcribed RNAs for transfection.

In the present study, we developed a new infectious cDNA for DENV-2, stably cloned into the BAC system under the control of the CMV promoter. The generated infectious cDNA was successfully rescued and constitutes a useful tool for improving our knowledge of the role of structural and non-structural proteins during the life cycle of DENV, as well as the role of naturally occurring mutations generated in circulating strains during epidemic spread, because of the possibility of evaluating their direct effect on virus replication, assembly and pathogenesis, through the use of isogenic variants with punctual mutations. Additionally, *EGFP*-bearing clone of DENV-2 was constructed, which expanded our knowledge of the constrictions of the viral genome for the generation of reporter viruses.

2. Materials and methods {#sec0010}
========================

2.1. Cells and viruses {#sec0015}
----------------------

The sequence of the DENV type 2 New Guinea C prototype strain (DENV-2 NGC), originally isolated from a clinical case of dengue fever in New Guinea in 1944 (GenBank accession number: EU854293), was used to assemble the infectious clone. African Green Monkey kidney (Vero) cells were obtained from the American Type Culture Collection (ATCC number: CCL-81) and maintained as low passage cultures (up to passage 10) in Dulbecco\'s Modified Eagle Medium (DMEM) (Gibco BRL, Carlsbad, CA, USA), supplemented with 2--10% heat-inactivated fetal bovine serum (FBS), 2 mM [l]{.smallcaps}-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin and incubated at 37 °C, 5% CO~2~ atmosphere and 95% relative humidity. C6/36 cells, derived from whole larvae of *Aedes albopictus* (ATCC number: CRL-1660), were cultured in Leibovitz\'s L-15 medium (Gibco BRL, Carlsbad, CA, USA), supplemented with 2--10% FBS and 20 mg/mL tryptose phosphate broth and incubated at 28 °C, 5% CO~2~ atmosphere and 95% relative humidity. A viral stock of DENV-2 NGC M2 was produced by inoculating C6/36 cells at a multiplicity of infection (MOI) of 0.01 plaque-forming units (PFU)/cell. The supernatants were collected at 96 h postinfection (hpi), cleared from cell debris through low-speed centrifugation, aliquoted and stored at −80 °C. For virus titration using a plaque assay, Vero cells were infected with serially diluted virus supernatants, incubated at 37 °C with an overlay containing carboxymethylcellulose, fixed with paraformaldehyde and stained with Crystal Violet at 9 days post-infection (dpi), as previously described ([@bib0195]). Because of the small plaque size phenotype of the parental DENV-2 NGC M2 strain and the derived infectious clone, the plaques were counted and captured using an inverted light microscope with minimal magnification (4× objective). The ImagePro Plus 3.1 software (Media Cybernetics, Silver Springs, MD, USA) was used to delimitate the plaques, and their diameters were estimated by ruling the images with a scale obtained from the microscope configuration.

2.2. Plasmids and bacterial strains {#sec0020}
-----------------------------------

The plasmids pBeloBAC11 ([@bib0145], [@bib0270]) and pBAC-TGEV5′-3′ ([@bib0280]), kindly provided by Dr. Luis Enjuanes (Centro Nacional de Biotecnología CNB-CSIC, Madrid, Spain), were used for assembling the infectious DENV cDNA clone flanked by the cytomegalovirus (CMV) immediate-early promoter, the Hepatitis Delta Virus Ribozyme (HDV-RZ) and the bovine growth hormone (BGH) termination and polyadenylation signal sequences. BAC propagation and manipulation was performed in *E. coli* DH10B (Gibco BRL, Carlsbad, CA, USA) as previously described ([@bib0310]). The enhanced green fluorescence protein (*EGFP*) and synthetic *Renilla* Luciferase (*hRLuc*) genes were amplified from plasmids pEGFP-N2 (BD Biosciences Clontech, Palo Alto, CA, USA) and psiCHECK-2 (Promega Corp., Madison, WI, USA), respectively. Plasmid DNA purification was performed using QIAprep Spin Miniprep and QIAGEN Large-Construct Kits (QIAGEN GmbH, Hilden, Germany). QIAquick PCR purification kit (Qiagen^®^, Chatsworth, CA, USA) was used to purify highly specific PCR products. Restriction endonuclease-digested vectors and inserts exceeding 4 kb were purified through QIAEX II gel extraction kit (Qiagen^®^, Chatsworth, CA, USA).

2.3. Viral RNA extraction and cDNA synthesis {#sec0025}
--------------------------------------------

Viral RNA was isolated from supernatants of DENV-infected C6/36 cells using QIAamp Viral RNA minikit (Qiagen^®^, Chatsworth, CA, USA), according to the manufacturer\'s instructions. SuperScript^®^ III First-Strand Synthesis System (Life Technologies Corp., Carlsbad, CA, USA) was used to generate cDNAs, although some modifications were implemented depending on the specific downstream requirements. Viral RNA (∼1 μg) was mixed with 10 to 50 ng of random hexamers or 10 pmol of a gene-specific primer, 1 mM of each dNTP and DEPC-treated water to a final volume of 10 μL, incubated at 65 °C for 5 min and immediately transferred to an ice--water bath for 2 min. After mixing with the other RT components, final concentrations were: 1X RT buffer, 0.5 to 2.5 ng/μL random hexamers or 0.5 μM gene-specific primer, 5 mM MgCl~2~, 0.5 mM each dNTP, 10 mM DTT, 40 units RNAseOUT™ and 200 units SuperScript III^®^ RT. Finally, 1 μL of RNAse H was added to each reaction and incubated at 37 °C for 20 min. Lower concentration of random hexamers during cDNA synthesis allowed the amplification of larger DNA fragments (approximately 4 kb in length). Additionally, annealing of a specific primer on the last 27 nucleotides of the viral RNA genome during cDNA synthesis permitted amplification of the 3′ end of DENV genome.

2.4. Cloning strategy for construction of a DENV infectious cDNA under the control of the CMV promoter {#sec0030}
------------------------------------------------------------------------------------------------------

The BAC clone of the full-length DENV genome under the control of the CMV promoter (pBAC-DENV-FL) was generated through PCR amplification, overlapping PCR and the sequential cloning of the amplified products as shown in [Fig. 1](#fig0015){ref-type="fig"} . The first step was the selection of naturally occurring unique recognition sites in the DENV genome spaced at approximately 3 to 4 kb. The selected *Sph* I (at position 1385), *Nsi* I (at position 4701) and *Pml* I (at position 8834) restriction sites were absent in pBeloBAC11. The second and third steps were the generation (PCR 1, 2, 5, and 6, overlapping PCR 1 and 2) and cloning of the fusion fragments (Cloning 1 and 2). The fusion of the CMV promoter sequence to the DENV 5′UTR and the partial structural region (nt 1 to 1384) was performed through overlapping PCR containing both fragments in equimolecular quantities (up to 100 ng of the larger PCR product) and forward (CMV5) and reverse (DEN2L3) primers of the first and second fragment to be fused, respectively. Thermal conditions included an optimal annealing temperature for the overlapping region, and initial amplification (1 to 10 cycles) in the absence of primers to allow the annealing and extension of the single-stranded templates. Cloning 1 facilitated the insertion of a multiple cloning site containing the restriction sites *Sph* I, *Nsi* I, *Pml* I and *Hind* III, used in the subsequent assembly. The last part of the non-structural region and the 3′UTR (nt 8835 to 10723) fused to HDV-RZ and BGH termination and polyadenylation signals to stabilize the mRNA transcribed from the CMV promoter and for proper processing to generate the DENV 3′ end, was obtained by overlapping PCR using the primers DEN2L5 and BGH3 and cloned in the previously described construct by using *Pml* I and *Hind* III (Cloning 2). The fourth and fifth steps involved the assembly of the full-length DENV infectious clone through amplification of two internal genome fragments \[PCR 3 comprising the remaining structural region and the partial non-structural region (nt 1385 to 4701) and PCR 4 spanning most of the non-structural region (nt 4702 to 8834)\], which were independently cloned into pBeloBAC11, sequenced and subsequently used in the corresponding cloning step (Cloning 3 and 4). The oligonucleotides used for PCR amplification and sequencing ([Table 1](#tbl0005){ref-type="table"} ) were designed using PrimerSelect module from LaserGene^®^ version 7.2.1 (DNASTAR Inc. 2007; Madison, WI, USA.). Oligonucleotide BGH3 was designed to eliminate the natural *Sph* I restriction site at the termination and polyadenylation signals of BGH gene to avoid interference with the cloning strategy. The designs were assessed to verify the secondary structure at the 5′- and 3′-UTRs, and the absence of changes in the ORF or stop codons in the coding region. All fragments were amplified through PCR using the Platinum^®^ *Pfx* DNA polymerase (Life Technologies Corp., Carlsbad, CA, USA). For cloning, the digested plasmids were dephosphorylated by using shrimp alkaline phosphatase (Promega Corp., Madison, WI, USA), ligated at different equimolecular quantities through T4 DNA ligase (New England BioLabs Inc., Ipswich, MA, USA) and used to transform electrocompetent DH10B as previously described ([@bib0310]). Depending on the construct, the identification of recombinant plasmids was performed by blue/white colony screening, restriction analysis or PCR, and sequencing of at least five clones using the corresponding sequencing oligonucleotides (Suppl. Tables 1--4) before the next cloning step.Fig. 1Strategy to assemble a DENV infectious cDNA clone as a BAC: A four-step cloning strategy, in which the overlapping cDNA fragments, termed overlapping PCR 1, PCR 2, PCR 3 and PCR 4, were sequentially cloned into the plasmid pBeloBAC11 and used to generate the infectious clone pBAC-DENV-FL. This plasmid includes the CMV promoter precisely joined to the DENV genome, followed by the hepatitis delta virus ribozyme (RZ) and the bovine growth hormone termination and polyadenylation sequences (BGH). The genomic positions of the relevant restriction sites used for the assembly of the full-length cDNA clone are illustrated at the top.Table 1Oligonucleotides used for the amplification, cloning and quantification of partial DENV genome fragments.Oligonucleotide nameOrientationRestriction endonucleasesAmplicon nameSequence (5′ → 3′)[a](#tblfn0005){ref-type="table-fn"}, [b](#tblfn0010){ref-type="table-fn"}CMV5F*Sfo* ICMV, CMV-DEN2 5′aatgat[ggcgcc]{.ul}ttgacattgattattgactagttattaatagCMV3RCMVggtccacgtagactaacaactacggttcactaaacgagctctgcDEN2L5FDEN2 5′agttgttagtctacgtggaccgacaaagacagDEN2L3R*Hind* III; *Pml* I; *Nsi* I; *Sph* IDEN2 5′, CMV-DEN2 5′cgcg[aagctt]{.ul}tggc[cacgtg]{.ul}cagg[atgcat]{.ul}gact[gcatgc]{.ul}tcttcccctgagtgaggtgDEN2R5F*Pml* IDEN2 3′, DEN2 3′-RZ-BGHgaagtcgg[cacgtg]{.ul}aggctgttgaagatagt3UTR-RZ-RRDEN2 3′atgccgacccagaacctgttgattcaacagcaccattRZ-FFRZ-BGHaacaggttctgggtcggcatggcatctccacctcctcgBGH3R*Hind* III; *Sac* IIRZ-BGH, DEN2 3′-RZ-BGHgccct[aagcttccgcgg]{.ul}tcgagctctccccaAcatgcctgctattgtc[c](#tblfn0015){ref-type="table-fn"}DENV1385-4701FF*Sfo* I1385-4701, 1385-ENVaatgat[ggcgcc]{.ul}ggaatacaccattgtgataacDENV1385-4701RR*Sph* I1385-4701, NS1-4701gaaga[gcatgc]{.ul}tggttcaatcctctttcctttatDENV4702-8834FF*Sph* I4702-8834gaaga[gcatgc]{.ul}ccagatcggagccggagtttacaaDENV4702-8834RR*Sph* I4702-8834gaaga[gcatgc]{.ul}accagctcccaaaacctactatctNS1-FF*Sfo* I; *Mlu* INS1-4701aatgat[ggcgcc]{.ul}gcgc[acgcgt]{.ul}acgctgtatttgggagttatENV-RR*Mlu* I1385-ENVgcgc[acgcgt]{.ul}ggcctgcaccataactcccaaatPEGFP-FF*Mlu* IEGFPgcgc[acgcgt]{.ul}atggtgagcaagggcgaggagPEGFP-RR*Mlu* IEGFPgcg[cacgcg]{.ul}tcttgtacagctcgtccathRLuc-FF*Mlu* IhRLucgcg[cacgcg]{.ul}tatggcttccaaggtgtahRLuc-RR*Mlu* IhRLucgcg[cacgcg]{.ul}ttaactgctcgttcttcagNS5_FFNS5tcacaccatttccatgagttaatcaNS5_RRNS5cgggctctaccaatcagttcaNS5_DENV (probe)FFAM-ccgcgtacttgtagttccatgcagaaacc[^2][^3][^4]

2.5. Insertion of EGFP and hRLuc reporter genes between viral E and NS1 genes into the DENV infectious cDNA {#sec0035}
-----------------------------------------------------------------------------------------------------------

The *EGFP* and *hRLuc* genes were cloned into the *envelope-nonstructural 1* (*E-NS1*) intergenic region of the DENV infectious cDNA as shown in [Fig. 4](#fig0030){ref-type="fig"}. The recognition peptide for cleavage through the cellular signalase present in the lumen of the endoplasmic reticulum was conserved in the 5′ end of the *NS1* gene ([@bib0035]), while the recognition sequence at the 3′ end of the *E* gene was not conserved, facilitating the expression of the reporters as fusion proteins with E protein (E-EGFP and E-hRLuc) after polyprotein processing. The cloning was performed in three steps. The first step involved the selection of the appropriate restriction site (*Mlu* I) for insertion of the reporter gene. The second step involved the PCR amplification of the 1385-ENV, EGFP/hRLuc and NS1-4701 fragments containing the *Sph* I, *Mlu* I, or *Nsi* I at the ends (PCR1 to 3). The third step involved the sequential cloning (Cloning 1 to 3) and replacement of the DENV1385-4701 fragment in the pBAC-DENV-FL using *Sph* I and *Nsi* I restriction sites (Subcloning 1) to obtain pBAC-DENV-FL-GFP or pBAC-DENV-FL-LUC. The oligonucleotides for the amplification and sequential insertion of *EGFP* and *hRLuc* reporter genes are shown in [Table 1](#tbl0005){ref-type="table"}. The oligonucleotides used for sequencing are shown in Suppl. Tables 5--7.

2.6. Transfection and recovery of infectious viruses from the cDNA clones {#sec0040}
-------------------------------------------------------------------------

Vero cells grown to 90% confluence in 24-well plates were transfected with 2 μg of the plasmid pBAC-DENV-FL, pBAC-DENV-FL-GFP or pBAC-DENV-FL-LUC, using 2 μL of Lipofectamine™ 2000 (Life Technologies Corp., Carlsbad, CA, USA) according to manufacturer\'s instructions. After an incubation period of 6 h at 37 °C, the transfection media were replaced and cells were incubated at 37 °C for 48 h. Cell supernatants were harvested and passaged twice on fresh C6/36 cells, and the recovered viruses of all three passages were analyzed as described below.

2.7. Analysis of viral RNA synthesis by two-step RT-qPCR {#sec0045}
--------------------------------------------------------

Viral RNAs from transfected/infected cell culture supernatants and intracellular viral RNAs were extracted with the QIAamp Viral RNA minikit and the RNeasy minikit (Qiagen^®^, Chatsworth, CA, USA), respectively, according to the manufacturer\'s instructions. All RNAs were treated with RQ1 RNase-free DNase I (Promega Corp., Madison, WI, USA) before use as templates for cDNA synthesis. For reverse transcription, the GoScript reverse transcriptase (Promega Corp., Madison, WI, USA) was used according to the manufacturer\'s instructions. The oligonucleotides NS5_F and NS5_R and the TaqMan^®^ MGB^™^probe NS5_DENV, used for quantitative amplification through qPCR, were designed using the Primer Express^®^ v2.0 software (Applied Biosystems, Foster City, CA, USA) ([Table 1](#tbl0005){ref-type="table"}). The Rotor-Gene^®^ Q Real-Time PCR system (Qiagen^®^, Chatsworth, CA, USA) was used for amplification and subsequent quantitative analyses. For the relative quantification of the viral RNA levels in the cellular lysates, the 2^−ΔΔ*CT*^ method ([@bib0185]), normalized to the endogenous 18S ribosomal RNA (Applied Biosystems, Foster City, CA, USA) reference gene, was used. For the absolute quantification of viral RNA copies in the cell culture supernatants, a standard plasmid was constructed by cloning the DENV NS5 region, comprising the target for oligonucleotides and probe hybridization into the pGEM^®^-T Easy vector system (Promega Corp., Madison, WI, USA) (Suppl. Fig. 1).

2.8. Immunofluorescence and confocal microscopy {#sec0050}
-----------------------------------------------

At different times post-transfection, Vero cells grown on coverslips in 24-well plates were fixed with paraformaldehyde 3.8% in cytoskeletal buffer for 30 min at 37 °C and treated as previously described ([@bib0085], [@bib0195]). Cell cultures transfected with EGFP-containing constructs were stained with Hoechst (nuclei), while the other cells were stained with the 4G2 mouse anti-E (flavivirus) monoclonal antibody ([@bib0110]) or the anti-E (DENV-2) polyclonal antibody (2133) (kindly provided by Dr. Eva Harris). The 4G2 monoclonal antibodies were collected from a hybridoma cell line (ATCC number: HB-112) cultured in ATCC Hybri-Care, supplemented with 10% FBS, incubated at 37 °C in a 5% CO~2~ atmosphere and 95% relative humidity. The images were obtained using a Spinning Disk Confocal microscope IX-81 (Olympus Corporation, Tokyo, Japan) equipped with a IX2-DSU (disk scanning unit) module (Olympus Europa Holding GmbH, Hamburg, Germany) and a digital CCD camera ORCA-*R* ^2^ (Hamamatsu Photonics K. K., Japan) and analyzed using Xcellence Pro 1.2 software (Olympus Soft Imaging Solutions GmbH, Münster, Germany).

2.9. Renilla luciferase activity assay {#sec0055}
--------------------------------------

Vero cells cultured in 6-well plates and transfected with pBAC-DENV-FL-LUC were lysed with 500 μL of lysis buffer from the *Renilla* Luciferase assay system (Promega Corp., Madison, WI, USA) at 24 and 48 h post-transfection (hpt) according to the manufacturer\'s instructions. Subsequently, a 20-μL aliquot of the lysate was mixed with 100 μL of the Assay Reagent, and the luminescence was quantified in a GloMax96 microplate luminometer (Promega Corp., Madison, WI, USA).

2.10. Statistical analysis {#sec0060}
--------------------------

For quantitative analyses, the experiments were performed independently three times, using three replicates for each experimental point. The results were expressed as the means ± standard error of the mean (SEM). Student\'s *t*-test (two-tailed) was used to determine the significance of the mean differences.

3. Results {#sec0065}
==========

3.1. Successful construction of a DENV infectious cDNA clone as a bacterial artificial chromosome under the control of the CMV promoter {#sec0070}
---------------------------------------------------------------------------------------------------------------------------------------

Using the cloning strategy depicted in [Fig. 1](#fig0015){ref-type="fig"}, an infectious clone was successfully constructed. The sequential cloning of the four fragments resulted in the generation of the constructs pBAC-CMV-DEN2-5′, pBAC-CMV-DEN2-5′3′-BGH, pBAC-DENV-First and finally the DENV infectious clone pBAC-DENV-FL. After elimination of one non-synonymous mutation at the *NS5* gene (nt 9152) and two mutations at the 3′ UTR (nt 10316 and 10420) (data not shown), three synonymous mutations at the *E* and *NS3* genes (nt 1215, 2040 and 5067) and one non-synonymous mutation at the *NS3* gene (nt 5846) remained in the full-length clone compared with the parental DENV-2 NGC M2 strain ([Table 2](#tbl0010){ref-type="table"} ). Despite the potentially negative effect of the non-synonymous mutation, the presence of this mutation in several sequenced clones of pBAC-DENV4702-8834 suggested that the change was present at a high frequency in the mutant swarm of the parental strain and did not result from an error introduced during PCR amplification or plasmid propagation in *E. coli*.Table 2Synonymous and non-synonymous mutations present in the DENV full-length infectious clones respect to the parental strain.Strain/constructPromoterPosition[a](#tblfn0020){ref-type="table-fn"}1215 Envelope2040 Envelope5067 NS35846 NS3[b](#tblfn0025){ref-type="table-fn"}DENV2 NGC_M2N/ALys (− − A)Glu (− − G)Ile (− − U)Ile (− U − )pBAC-DENV-FLCMVLys → Lys (− − A →− − G)Glu → Glu (− − G →− − A)Ile → Ile (− − U →− − A)Ile → Thr (− U− → −C −)pBAC-DENV-FL-GFPCMVLys → Lys (− − A → − − G)--Ile → Ile (− − U →− − A)Ile → Thr (− U− → − C −pBAC-DENV-FL-LUCCMVLys → Lys (− − A →− − G)--Ile → Ile (− − U →− − A)Ile → Thr (−U − → − C−)[^5][^6]

3.2. Rescue of infectious DENV from the cDNA clone in Vero and C6/36 cells {#sec0075}
--------------------------------------------------------------------------

To recover infectious virus, Vero cells were transfected with the DENV cDNA clone. At \*\*48 hpt the cell supernatants were collected and used to inoculate C6/36 mosquito cell cultures. Three serial passages of the C6/36 culture supernatants were performed to increase the virus titer. The rescued recombinant full-length DENV (rDENV-FL) induced a clear cytopathic effect in C6/36 cells, characterized by syncytia formation, visible from the first passage ([Fig. 2](#fig0020){ref-type="fig"}A). All synonymous and non-synonymous mutations that characterized the infectious clone remained after three passages in C6/36 cells, as corroborated through sequencing (data not shown), thereby acting as genetic markers for the identification of rDENV-FL and differentiation from the parental strain. To evaluate the phenotypic properties of the rescued virus, the cytopathic effect ([Fig. 2](#fig0020){ref-type="fig"}B) and plaque size phenotype ([Fig. 2](#fig0020){ref-type="fig"}C) were analyzed in Vero cells and compared with those of the parental virus. The cytopathic effect, characterized by the presence of rounded cells in the supernatants, was visible after 7 dpi ([Fig. 2](#fig0020){ref-type="fig"}B), and both viruses induced the formation of small plaques with diameters ± standard deviations of 0.355 ± 0.168 and 0.404 ± 0.043 for the parental M2 and rDENV-FL strains, respectively ([Fig. 2](#fig0020){ref-type="fig"}D), without statistically significant differences. These results demonstrate the successful rescue of rDENV-FL in C6/36 cells and the attenuated phenotype of this virus in Vero cells, as expected from the parental strain.Fig. 2Phenotypic characterization of the rDENV-FL virus: (A) cytopathic effect (CPE) in C6/36 cells. C6/36 cells were mock infected, infected with the parental virus or infected during three passages with the rDENV-FL and subsequently analyzed for the induction of CPE through light microscopy. (B) CPE in Vero cells. Monolayers of Vero cells were mock infected, infected with the parental virus or the rDENV-FL and subsequently analyzed for the induction of CPE through light microscopy. (C) and (D) Plaque size phenotype. The plaque sizes of the rDENV-FL and the parental virus were analyzed as described in Section [2](#sec0010){ref-type="sec"}. Circles were drawn to delimitate the plaques and estimate the diameter, which were expressed in millimeters as the mean ± standard deviation. V1C2 corresponds to the history of the virus rescue (in this case, one passage in Vero cells and two passages in C6/36 cells).

In spite of having phenotypic evidence of a viral infection, the identity of the rescued virus was further confirmed through the detection of the DENV envelope protein in infected C6/36 cells by immunofluorescence. As expected, only rDENV-FL-infected cells were positive for the specific staining of the DENV envelope protein using a polyclonal antibody ([Fig. 3](#fig0025){ref-type="fig"}A). Finally, viral RNA levels from infected cell supernatants were quantified, and a corresponding increase similar to that previously observed in cytopathicity in C6/36 cells after serial passage was confirmed as a significant increase in the total number of viral RNA copies, primarily for passages 2 and 3 (*p*  \< 0.01) ([Fig. 3](#fig0025){ref-type="fig"}B). These results confirm the presence of the specific DENV antigen and the presence and increase in DENV genomes after serial passages of the rDENV-FL in C6/36 cells.Fig. 3Specific detection of rDENV-FL virus: (A) Envelope protein detection. C6/36 cells were mock infected or infected with rDENV-FL passage 2 and subsequently the envelope protein expression was analyzed through indirect immunofluorescence using the polyclonal antibody 2133 and a secondary antibody conjugated to Alexa Fluor^®^ 488. Nuclei were stained with Hoechst. (B) Viral genome detection. Supernatants of the serial passages of rDENV-FL in C6/36 cells were used for viral RNA extraction and RT-qPCR quantification. The error bars represent the standard error of the mean (SEM). ^\*\*^*p* \< 0.01.

3.3. The expression of EGFP as a fusion protein with the viral envelope protein could affect the assembly or exit of the viral progeny {#sec0080}
--------------------------------------------------------------------------------------------------------------------------------------

To construct a useful tool for the study of the cell biology of DENV infection, to track the envelope protein and viral particles, the reporter *EGFP* gene was fused to the 3′ end of the viral *envelope* gene, as depicted in [Fig. 4](#fig0030){ref-type="fig"} (see Section [2](#sec0010){ref-type="sec"} for details). The *EGFP* reporter gene was successfully inserted into the intergenic region *E-NS1*, facilitating the elimination of the synonymous mutation located at position 2040 in the previously obtained infectious clone ([Table 2](#tbl0010){ref-type="table"}). After transfection of the EGFP-bearing DENV recombinant clone (pBAC-DENV-FL-GFP) in Vero cells and two passages in C6/36 cells, no cytopathic effect was observed (data not shown), suggesting that the recombinant virus was not successfully rescued. To further evaluate the rescue, RNA was extracted from cell culture supernatants at different passages of the virus and measured through RT-qPCR. Despite a moderate increase in the viral RNA levels at passage 2 in C6/36 cells (*p*  \< 0.05) ([Fig. 5](#fig0035){ref-type="fig"}A), viral RNA levels were lower than those obtained for the DENV infectious clone without a reporter ([Fig. 3](#fig0025){ref-type="fig"}B). Indeed, EGFP-positive cells were not detected in cell cultures inoculated with the supernatant from this passage (data not shown), indicating that no infectious virus was successfully rescued. To rule out a defect in the transcription from the CMV promoter or translation from the proper ORF, the expression of EGFP in Vero cells transfected with the pBAC-DENV-FL-GFP construct was evaluated. EGFP-positive cells were detected at 24 hpt ([Fig. 5](#fig0035){ref-type="fig"}B), suggesting that viral polyprotein, including the reporter EGFP, were properly translated. Finally, to assess the ability of the CMV-transcribed RNAs to autonomously replicate and generate negative-sense viral RNAs from the viral RNA-dependent RNA Polymerase and non-structural proteins activity, RT-qPCR for detecting negative-sense viral RNAs was performed and significant amounts of DENV negative-sense RNA were detected at 24 hpt ([Fig. 5](#fig0035){ref-type="fig"}C).Fig. 4Strategy for the construction of *EGFP*- and *hRLuc*-bearing DENV infectious clones: A three-step cloning strategy, in which three overlapping cDNA fragments (PCR1 to PCR3) were sequentially cloned into the plasmid pBeloBAC11 and used to generate the plasmid pBAC-ENV-GFP/hRLuc-NS1-3. After verifying the nucleotide sequence, the *Sph* I-*Nsi* I fragment was cloned into pBAC-DENV-FL to generate pBAC-DENV-FL-GFP and pBAC-DENV-FL-LUC. The genetic structure of the DENV infectious clones expressing EGFP or hRLuc, the position of relevant restriction sites and the cleavage site for host cell signalase are illustrated.Fig. 5Characterization of the rDENV-FL-EGFP and rDENV-FL-LUC: (A) Viral genome quantification. The supernatants from passages 1 and 2 of the rDENV-FL-EGFP in C6/36 cells were used for viral RNA extraction and RT-qPCR quantification. (B) EGFP expression. Vero cells were mock transfected or transfected with the plasmid pBAC-DENV-FL-EGFP, fixed at 24 hpt, stained with Hoechst and visualized through confocal microscopy. (C) and (E) Viral genome replication analysis. Cellular lysates from Vero cells transfected with (C) pBAC-DENV-FL-EGFP or (E) pBAC-DENV-FL-LUC were collected at 24 and 48 hpt and used for total RNA extraction and RT-qPCR quantification of negative strand of the viral RNA. (D) Luciferase activity. Cellular lysates from Vero cells transfected with the plasmid pBAC-DENV-FL-LUC were collected at 20 and 44 hpt, and after the first passage in Vero cells, the luciferase activity was quantified. The values are given in Relative Luciferase Units (RLU). The error bars represent the SEM. ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001.

To evaluate whether the negative effect can be attributed to the nature of the *EGFP* gene, as a result of the production of a non-functional fusion protein by incorrect folding or improper subcellular localization, another reporter gene (*hRLuc*) was cloned and evaluated in the same manner. This new molecular construct (pBAC-DENV-FL-LUC) exhibited the same mutation pattern as pBAC-DENV-FL-GFP ([Table 2](#tbl0010){ref-type="table"}). The ability of the clone to transcribe from the CMV promoter and translate from the correct ORF was demonstrated through the presence of luciferase activity ([Fig. 5](#fig0035){ref-type="fig"}D). The viral RNA and replicase complex activity was demonstrated through the presence of significant amounts of negative-sense viral RNA strands ([Fig. 5](#fig0035){ref-type="fig"}E). However, a total absence of the cytopathic effect in Vero and C6/36 cells (data not shown) and a failure to recover infectious particles after one passage ([Fig. 5](#fig0035){ref-type="fig"}D) was demonstrated.

4. Discussion {#sec0085}
=============

The development of reverse genetics systems for several RNA viruses has become an invaluable tool for multiple purposes. DENV research has greatly benefited from these developments in several ways, ranging from the study of gene and protein function to vaccine generation and antiviral screening ([@bib0040], [@bib0090], [@bib0120], [@bib0125], [@bib0140], [@bib0220], [@bib0260], [@bib0300], [@bib0305]). The rational design and construction of the DENV infectious clone as a BAC under the control of the CMV promoter described in the present study facilitated the successful rescue of DENV infectious particles, leading to plaque formation with phenotypic features similar to the parental strain. The standard deviation of the plaque diameter for rDENV-FL was smaller than that for the parental strain (DENV-2 NGC M2), reflecting the clonal origin of the rDENV-FL strain and suggesting its convenience for studying the effect of single mutations, where highly homogeneous viral populations are required. The parental strain showed a very attenuated phenotype, with plaque diameters significantly smaller than those of a highly adapted DENV strain (called DENV-2 NGC N2) (Suppl. Fig. 2). The parental (M2) and highly adapted (N2) DENV-2 NGC strains belong to the same original clinical isolation (New Guinea C); however, different passage histories, genetic drift and selection has led to sequence differences and extremely different phenotypes. The parental strain was chosen for cloning because of its smaller plaque size and the biological safety concerns for the potential derivation of a novel viral vector from the DENV infectious clone. The dramatic plaque size phenotype differences between these two closely related DENV strains reflect the usefulness of the infectious clone for studying virulence determinants and pathogenesis.

Despite the presence of a candidate for donor splicing site at position 3395 (*NS1* gene) in the full-length DENV genome (Suppl. Tables 8 and 9), a commonly high number of false-positive splice sites predictions ([@bib0030]) and the existence of viable DENV replicons under the control of the CMV promoter, including the entire *NS1* gene ([@bib0010], [@bib0170], [@bib0175], [@bib0230]), are consistent with this site not being strictly used for splicing. The sequencing of several fragments amplified from the viral RNA extracted after serial passages in C6/36 cells demonstrated the stability and integrity of these viral genome regions. The functionality of the rDENV-FL was evidenced by productive infection when the supernatants of transfected/infected cells were used to inoculate fresh cellular cultures. Although some DNA-launched replicons of DENV under the control of the CMV promoter have been previously described ([@bib0010], [@bib0165], [@bib0170], [@bib0175], [@bib0230]), to the best of our knowledge, this study presents the first DENV infectious clone under the control of the CMV promoter for the recovery of recombinant viruses without the need for *in vitro* transcription.

In addition to the DENV infectious clone, we generated an *EGFP*-bearing molecular clone (pBAC-DENV-FL-GFP), expressing EGFP as a fusion protein with the viral envelope protein in an attempt to generate a clone in which the early (entry and membrane fusion) and late (assembly of new viral particles) steps and subcellular localization of the envelope protein during infection could be tracked. Fusion proteins are crucial for deciphering viral intracellular trafficking during the early and late steps of infection ([@bib0025]). However, in the present study, the fusion of the EGFP protein had a profoundly negative effect in virus rescue. Although autonomous viral genome replication was demonstrated for this clone after transfection, the detection of viral RNA (low levels) at passage 2 in C6/36 cells was not supported by the presence of the reporter protein. This disparity could be explained by the higher sensibility of the RT-qPCR to detect low levels of RNA molecules and the potential presence of a very low number of undetected fluorescent (EGFP) cells in those cultures at passage 2. The results suggest a negative impact of the fused EGFP in viral function (packaging, exit, or infectivity of the viral progeny). Undetectable or minimal levels of infectious virus in the supernatants of transfected cells have been previously observed when the reporter *GFP* gene was inserted into the anchored-*C* region of a DENV-2 infectious clone, and a significant defect in virus infectivity through the insertion of the reporter gene has also been suggested ([@bib0170]).

Because of the size and potential spatial constrictions of the core structure, our initial design did not contemplate the fusion of the reporter to the capsid protein, but to the carboxyl-terminus of the envelope protein, which has a major size and dynamic structure. A previous study using *Yellow fever virus* showed the successful insertion of the *EGFP* reporter gene in the *E-NS1* intergenic region through the duplication of the stem-anchor region of the E protein ([@bib0020]). Although that design avoided the negative effects associated with flavivirus E-NS1 separation, as the carboxyl-terminus of the envelope protein serves as a signal sequence required for the production of glycosylated NS1 protein ([@bib0060]), the duplication of the ER signal peptidase recognition site at E-NS1 resulted in the separation of the E and EGFP proteins and was therefore not useful for protein and/or virion tracking.

Recently, an infectious clone of DENV-2, expressing the *EGFP* reporter gene, was successfully constructed ([@bib0265]). This molecular construct was a powerful tool for cell-based screening assays to identify antiviral molecules and their mechanisms of action. However, the EGFP protein was not fused to any viral structural protein and therefore, this EGFP-bearing DENV recombinant clone facilitated neither the tracking of individual particles outside the cell nor the examination the subcellular localization of any viral structural protein during the early and late steps of the DENV life cycle. Future attempts to mark at least one viral structural protein for tracking the course of infection should evaluate other positions for fusion of the reporter gene, including the carboxyl-terminus of the prM/M protein and the amino-terminal of the envelope protein.

Similarly, only two DENV infectious clones expressing the luciferase gene have been previously reported as excellent alternatives for quantitative analysis in the high-throughput screening of antiviral compounds ([@bib0305]) and bioluminescence imaging of DENV infection *in vivo* ([@bib0265]). These reporter-bearing infectious clones contain the 5′UTR, the sequence encoding the 38 N-terminal amino acids of the capsid protein, the *hRLuc* reporter and the FMDV2A sequence, followed by the full-length DENV ORF, which includes the complete capsid gene. The results from the present study, with a molecular clone constructed using a different strategy (pBAC-DENV-FL-LUC), confirm the correct expression of luciferase and the replicase complex function after transfection. The non-proportional increase between the Relative Luciferase Units and the negative-sense viral RNA could be explained by the principle of the methods, stability of the reporter protein or apoptotic cell death of the transfected cells at 36 hpt and later, leading to viral RNA decline, as it was observed for other constructs (DENV-derived replicons) (unpublished data). However, the absence of cytopathic effects and luciferase activity after one passage suggests that alterations of the carboxyl-terminus of the envelope protein through fusion with the reporter hRLuc negatively impacted virus morphogenesis or the infectivity of the viral progeny, consistent with the data obtained for the EGFP-bearing clone. Despite the negative impact on the production of virions, these results help to delimit future studies concerning the fusion of reporters to DENV structural genes.

Taken together, the results shown in the present study demonstrate the successful construction of a novel CMV-driven infectious clone of DENV-2 in a BAC for the effective recovery of infectious particles displaying phenotypic characteristics similar to the parental strain. This infectious clone will overcome the costs and degradation risks associated with *in vitro* transcription and RNA manipulation, and this clone will also serve as a backbone to assess the potential positions for fusion with any reporter gene. In addition, this construct will be useful for a number of applications in the study of DENV biology, molecular pathogenesis, evolution and the development of viral vectors.

5. Conclusions {#sec0090}
==============

We successfully cloned and expressed the whole DENV-2 genome as an infectious BAC under the control of the CMV promoter. The use of this promoter allows the generation of infectious viruses avoiding the limitations related to *in vitro* RNA synthesis and RNA transfection methods. This infectious full-length cDNA clone is a useful tool that could be implemented in the study of DENV biology, antiviral screening and vaccine development.

Appendix A. Supplementary data {#sec0100}
==============================
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[^1]: Present address: Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.

[^2]: The underlined sequences correspond to recognition sites for the restriction endonucleases used in the cloning strategy.

[^3]: The boldface sequences correspond to oligonucleotide regions that hybridize with the DENV genome.

[^4]: The uppercase letter in the BGH3 sequence corresponds to a punctual mutation introduced to eliminate the *Sph* I restriction site. F: forward; R: reverse; FAM: 6-carboxyfluorescein.

[^5]: Positions with respect to the reference strain DENV-2 NGC (GenBank accession number: M29095.1). Specific changes in the nucleotide sequence and codon position are detailed in parenthesis.

[^6]: Non-synonymous mutation present in more than one partial clone (pBAC-DENV4702-8834 clones 2 and 4) before assembly of the full-length construct. N/A: not applicable.
